Russia may collaborate with India for the manufacture of the Sputnik V COVID 19 Vaccine

Brand Name

Russia may collaborate with India for the manufacture of the Sputnik V COVID 19 Vaccine

Russia and India may join hands for the making of the Sputnik V Shots

Wednesday, 26th August 2020


 In a major development pertaining to the Coronavirus vaccine, Russia has revealed its wish to collaborate with the government of India for the manufacturing of the Sputnik V Covid-19 vaccine, said a Government official on Tuesday.

 

In this context it is worthwhile to note that Russia had claimed to have manufactured the first Coronavirus vaccine; the Sputnik V vaccine which is an effective adenoviral human vector vaccine capable of destroying the deadly COVID-19 vaccine. The Gamaleya National Research Institute of Epidemiology and Microbiology has developed this vaccine. A report from the Russian researchers last week declared that currently the vaccine is in the Phase 3 of its clinical trial.

 

"As far as Sputnik V vaccine (Covid-19 vaccine developed in Russia) is concerned, both India and Russia are in communication. Some initial information has been shared while some detailed information is awaited," said Union Health Secretary, Rajesh Bhushan on Tuesday while answering a question as to whether the government of Russia has presented the Indian government with a formal and official request for the Sputnik V manufacturing in our country, India.

 

"The Vaccine and Research and Development Taskforce co-chaired by Dr Vinod Paul (Member of the Niti Aayog and Professor Vijayraghavan who is Principal Scientific Advisor) will examine the suggestions for potential collaborations on vaccine development. The committee, with inputs from members, particularly the Department of Biotechnology and the ICMR, will examine the information on the matter and will link potential collaborators where robust and value-added collaborations are feasible and meaningful," said an official from the government of India.

 

"More than 40,000 people in 45 medical centers are participating in a randomized, double-blind, placebo-controlled multicenter clinical study of the efficacy, immunogenicity, and safety of the Sputnik V vaccine in Russia, simultaneously with the vaccination of volunteers from risk groups," said the Russian researchers last week at a virtual press briefing.

 

In his reply to a question asking him about his joint venture plans with the Indian pharmaceutical companies, Kirill Dmitriev, the CEO of the Russian Direct Investment Fund (RDIF) said: "Yes, production of the vaccine is an important issue, we look to Indian drug producers to co-partner as we believe India is capable of producing Gamaleya Institute vaccine and it is important to say that these partnerships should produce a vaccine that enables us to cover the demand that we have received."

 

The vaccine’s Phase 1 & 2 clinical trials have been successfully completed on the 1st of August. "All the volunteers are feeling well, no unforeseen or unwanted side effects were observed. The vaccine-induced strong antibody and cellular immune response. Not a single participant of the current clinical trials got infected with Covid-19 after being administered with the vaccine," said the Gamaleya National Institute’s research team.

 

"The high efficacy of the vaccine was confirmed by high precision tests for antibodies in the blood serum of volunteers (including analysis for antibodies that neutralize the coronavirus), as well as the ability of the immune cells of the volunteers to activate in response to the spike S protein of the coronavirus, which indicates the formation of both antibody and cellular immune vaccine response," said the Russian researchers.

 

Phase 3 of the clinical trial of the vaccine involving over 2,000 subjects in Russia, a couple of Middle Eastern as well as Latin American countries begun on the 12th of August. A registration certificate was issued for the vaccine from the Ministry of Health, Russia on the 11th of August and in accordance with the emergency regulations adopted at this time of the Coronavirus pandemic it can be made use of for vaccinating the Russian population. The vaccine’s mass production, they said, is likely to begin in the month of September, 2020.

 

 

Source: Times of India


Top Stories
Download video from a Converthub online ..
Impact Feature: अमेरिकन ..
South Newsmakers of Week: Ram Charan & S..
What Makes Gandhis CWC a Team Amidst the..
Kerala Sees a Dip in Total Covid-19 Case..
Bangladesh “Just not Good Enough”, S..
Udanpirappe Movie Review: A family drama..
5 Superfood-Enriched Products for Health..
5 Superfoods Against Anxiety and Stress..
5 Small Lifestyle Changes You Can Make t..